A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

PF-07976016 is under development for the treatment of obesity. It is administered as oral solution and oral suspension. The drug candidate acts by targeting gastric inhibitory peptide (GIPR).

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Breast Cancer.

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure.

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.